Phathom's Inflection Point: First Profits, but Payer 'Friction' Caps Near-Term Growth
GI-first pivot delivers operating profitability and first positive cash flow, yet a newly flagged access 'friction' forces a modest guidance trim and sets up 2026 as an execution test.
PHAT · Earnings Call · 2026-07-30
The Inflection: From Burn to Positive Operating Profit
Phathom Pharmaceuticals (PHAT) reached a defining moment in Q2 2026: “for the first time in Phathom's history and ahead of our guidance, we generated positive operating profit in Q2, excluding stock-based compensation.” — Steven Basta, President and CEO · 2026-07-30 Revenue surged 88% year-over-year to $74.3M, while cash operating expenses fell 34%, and the company generated its first-ever positive cash from operations (~$1.6M). Sanjeev Narula, CFO, called it “an important inflection point for Phathom.” — Sanjeev Narula, Chief Financial and Business Officer · 2026-07-30 The numbers confirm a successful pivot: after years of losses, the trajectory toward profitability is finally visible. The company reiterated belief in a $1B GI opportunity, with a second $1B from primary care later.
The New Headwind: Payer 'Friction'
The quarter's shine was tempered by a newly emphasized theme: friction. Management reported that while physicians are enthusiastic about VOQUEZNA, they face hurdles in the prior-authorization (PA) process, particularly for less severe GERD patients. Steve Basta summarized in prepared remarks:
We are hearing from our field team and in our market research that physicians are encountering friction in the process of obtaining VOQUEZNA for their GERD patients.
This friction is not an access problem—coverage is strong—but a workflow and perception issue. Physicians must document prior PPI failures, office staff navigate PA submissions, and some patients struggle to fill. The company trimmed 2026 revenue guidance to $310–325M (from a prior range implied by earlier commentary) to reflect this headwind. The stock has sold off ~30% over the past 90 days, reflecting investor concern about decelerating script growth.
Tactical Response and New Catalysts
Phathom's response is multi-pronged: it is educating offices, simplifying documentation, and actively steering scripts to Blink pharmacy for better support. Basta noted that top prescribers have already streamlined the process, so it is a unique value proposition of coaching. He also sees Blink as a facilitator, not just a cash-pay channel: “We think about Blink as a facilitating partner that helps physicians' offices get through the PA process as smoothly and as easily as possible” (component_hash="8596754131649437270").
Beyond execution, the pipeline offers two catalysts. First, the EoE Phase 2 trial completed enrollment ahead of schedule, with top-line data expected in Q4. Second, the company will initiate a Phase 3 as-needed trial for Non Erosive GERD in Q4, targeting patients who prefer on-demand relief over chronic daily therapy. Basta emphasized this is a market expansion, not cannibalization: “It's really about expanding to an incremental market opportunity” (component_hash="6924737143894378607"). This could open a future DTC narrative and a distinct label.
Context and Priorities
The competitive landscape remains a recurring theme. On tegoprazan, management repeated its view that a second PCAB will expand the category, a stance echoed in prior quarters: “we are, in fact, tracking the evolution of Tegoprazan so as they start to build awareness.” — Steven Basta, President and CEO · 2026-04-30 They also remain disciplined on spending, with cash OpEx guidance of $235–245M for 2026 and a commitment to “durable cash flow positivity in 2027” (Sanjeev Narula, component_hash="1278448784708222678").
The Q1 fundamentals already showed progress, but the Q2 call reflects an even stronger improvement. The key question now is whether the friction mitigation efforts can restore script growth momentum. As Basta said in a prior quarter, “We are feeling and hearing from the field the same kinds of things that you can see in the IQVIA or the IMS numbers” (component_hash="3141877393535393852"), and that conviction will be tested over the back half of 2026.